Telomir Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues | $— | $— | $— | $— |
| Operating costs: | ||||
| General and administrative expenses | 493,309 | 386,951 | 2,386,850 | 7,264,808 |
| Research and development expenses | 251,887 | 759,525 | 1,164,358 | 1,139,360 |
| Total operating costs | 745,196 | 1,146,476 | 3,551,208 | 8,404,168 |
| Interest income | 41,879 | 44,182 | 139,699 | 53,544 |
| Interest expense | (1,908) | — | (6,191) | (1,388) |
| Total other income, net | 39,971 | 44,182 | 133,508 | 52,156 |
| Net loss | $(705,225) | $(1,102,294) | $(3,417,700) | $(8,352,012) |
| Deemed dividend | — | — | (46,113,903) | — |
| Net loss attributable to common stockholders | $(705,225) | $(1,102,294) | $(49,531,603) | $(8,352,012) |
| Basic and diluted net loss per share attributable to common stockholders | $(0.01) | $(0.03) | $(0.90) | $(0.27) |
| Basic and diluted weighted average common stock shares outstanding | 68,774,956 | 32,398,906 | 54,790,448 | 31,039,964 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.